SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hyperion Trading Segregated Portfolio

(Last)

(First)

(Middle)

C/O TMF LTD. GRAND PAVILLION COMM. CTR

2ND FL., 802 WEST BAY ROAD, PO BOX 10338

(Street)

GRAND CAYMAN

KY1-1003

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Raptor Pharmaceutical Corp [ RPTP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2013

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/14/2013		S		15,000	D	$10.7	6,219,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/15/2013		S		15,000	D	$11.03	6,204,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/16/2013		S		15,000	D	$11.5	6,189,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/19/2013		S		15,000	D	$11.51	6,174,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/20/2013		S		55,000	D	$12.05⁽³⁾	6,119,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/21/2013		S		25,000	D	$12.25⁽⁴⁾	6,094,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/22/2013		S		65,000	D	$12.64⁽⁵⁾	6,029,000	D
Common Stock, par value $0.001 per share⁽¹⁾⁽²⁾	08/23/2013		S		74,300	D	$13.15⁽⁶⁾	5,954,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Contracts for Difference⁽⁷⁾	$12.29⁽⁸⁾	08/23/2013	08/23/2013	J/K⁽⁸⁾			700	⁽⁸⁾	⁽⁸⁾	Common Stock, par value $0.001 per share	700	$12.9⁽⁸⁾	421,006	D

Explanation of Responses:

1. The shares of common stock, $0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Sequoia Asset Management S.A., a company organized under the laws of Switzerland ("Sequoia").

2. The Common Shares and Contracts for Difference ("CFDs", and together with the Common Shares, the "Securities") reported herein represent transactions undertaken by the Reporting Person. Pursuant to Reg. Section 240.16a-1(a)(1), Sequoia, as the investment manager of the Reporting Person, is not deemed a beneficial owner of the Securities held by the Reporting Person or any other account managed by Sequoia. In the event that Sequoia is deemed a beneficial owner of the Securities held by the Reporting Person or any other account managed by Sequoia, pursuant to Reg. Section 240.16a-1(a)(2), its beneficial ownership is limited to its pecuniary interest, if any, in such Securities.

3. This price represents the weighted average purchase sale of the Common Shares on August 20, 2013, which were sold in multiple transactions ranging from $11.78 to $12.30, inclusive.

4. This price represents the weighted average purchase sale of the Common Shares on August 21, 2013, which were sold in multiple transactions ranging from $12.15 to $12.40, inclusive.

5. This price represents the weighted average purchase sale of the Common Shares on August 22, 2013, which were sold in multiple transactions ranging from $12.42 to $12.90, inclusive.

6. This price represents the weighted average purchase sale of the Common Shares on August 23, 2013, which were sold in multiple transactions ranging from $12.75 to $13.50, inclusive.

7. Agreement to sell the difference between purchase price and market value upon conversion.

8. On August 23, 2013, pursuant to an agreement between the Reporting Person and a securities broker (the "Issuer of the CFDs"), the Reporting Person converted 700 CFDs for $9,030.00, representing a conversion price of $12.90 per CFD, offset by $4,361.00, representing $6.23 per CFD (the purchase price of the CFD). The CFDs do not grant voting rights or dispositive rights over the Common Shares.

Remarks:

1. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the Staff of the Securities and Exchange Commission, upon request, the full information regarding the number of Common Shares bought at each separate price within the ranges set forth in this Form 4.

	/s/ David P.M. Blair and Richard A. Reinert	08/19/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.